Hormonal regulation of food intake

Physiological Reviews

Volumn 85, Issue 4, 2005, Pages 1131-1158

  Stanley, Sarah ^a   Wynne, Katie ^a   McGowan, Barbara ^a   Bloom, Stephen ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BOMBESIN; CHOLECYSTOKININ; ENDOCANNABINOID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; MELANOCORTIN; NEUROPEPTIDE; NEUROPEPTIDE Y; OPIATE; OXYNTOMODULIN; PANCREAS HORMONE; PANCREAS POLYPEPTIDE; PEPTIDE YY; PREPROGLUCAGON; RESISTIN;

ADIPOSE TISSUE; APPETITE; BODY WEIGHT; BRAIN STEM; ENDOCRINE FUNCTION; ENERGY EXPENDITURE; FOOD INTAKE; HORMONAL REGULATION; LIMBIC SYSTEM; NERVE CELL NETWORK; NONHUMAN; NUTRITIONAL STATUS; PRIORITY JOURNAL; REVIEW; REWARD;

ANIMALS; APPETITE; ENERGY METABOLISM; GASTROINTESTINAL HORMONES; HOMEOSTASIS; HUMANS; HYPOTHALAMIC HORMONES; PANCREATIC HORMONES; PEPTIDE HORMONES;

EID: 25444514533     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.00015.2004     Document Type: Review

References (461)

1. Abbott CE, Rossi M, Kim M, AlAhmed SH, Taylor GM, Ghatei MA, Smith DM, and Bloom SE. Investigation of the melanocyte stimulating hormones on food intake. Lack of evidence to support a role for the melanocortin-3-receptor. Brain Res 869: 203-210, 2000.
2. Abbott CR, Rossi M, Wren AM, Murphy KG, Kennedy AR, Stanley SA, Zollner AN, Morgan DG, Morgan I, Ghatei MA, Small CJ, and Bloom SR. Evidence of an orexigenic role for cocaine- and amphetamine-regulated transcript after administration into discrete hypothalamic nuclei. Endocrinology 142: 3457-3463, 2001.
3. Abel EL. Cannabis: effects on hunger and thirst. Behav Biol 15: 255-281, 1975.
4. Adrian TE, Bloom SR, Bryant MG, Polak JM, Heitz PH, and Barnes AJ. Distribution and release of human pancreatic polypeptide. Gut 17: 940-944, 1976.
5. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, and Bloom SE. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89: 1070-1077, 1985.
6. Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, Polak JM, and Bloom SR. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89: 494-499, 1985.
7. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, and Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252, 1996.
8. Air EL, Strowski MZ, Benoit SC, Conarello SL, Salituro GM, Guan XM, Liu K, Woods SC, and Zhang BB. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 8: 179-183, 2002.
9. Allen JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, and Bloom SR. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 30: 255-262, 1984.
10. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, and Polak JM. Neuropeptide Y distribution in the rat brain. Science 221: 877-879, 1983.
11. Alvarez BM, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, and Fernandez-Represa J. A peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obesity Surg 12: 324-327, 2002.
12. Anand BK and Brobeck JR. Localization of a "feeding center" in the hypothalamus of the rat. Proc Soc Exp Biol Med 77: 323-324, 1951.
13. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, and Small CJ. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279: 12005-12008, 2004.
14. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B III, Johnson RS, and Kahn CR. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372: 186-190, 1994.
15. Argyropoulos G, Rankinen T, Neufeld DR, Rice T, Province MA, Leon AS, Skinner JS, Wilmore JH, Rao DC, and Bouchard C. A polymorphism in the human agouti-related protein is associated with late-onset obesity. J Clin Endocrinol Metab 87: 4198-4202, 2002.
16. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
17. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, and Nakao K. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86: 4753-4758, 2001.
18. Arosio M, Ronchi CL, Gebbia C, Cappiello V, Beck-Peccoz P, and Peracclii M. Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. J Clin Endocrinol Metab 88: 701-704, 2003.
19. Asakawa A, Inui A, Ueno N, Fujimiya M, Fujino MA, and Kasuga M. Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20:1445-1448, 1999.
20. Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, and Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124: 1325-1336, 2003.
21. Asin KE, Gore PA Jr, Bednarz L, Holladay M, and Nadzan AM. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res 571: 169-174, 1992.
22. Atkinson RL and Brent EL. Appetite suppressant activity in plasma of rats after intestinal bypass surgery. Am J Physiol Regul Integr Comp Physiol 243: R60-R64, 1982.
23. Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN, Moizo L, Lehy T, Guerre-Millo M, Marchand-Brustel Y, and Lewin MJ. The stomach is a source of leptin. Nature 394: 790-793, 1998.
24. Bagdade JD, Bierman EL, and Porte B Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 46: 1549-1557, 1967.
25. Bagnasco M, Dube MG, Kalra PS, and Kalra SP. Evidence for the existence of distinct central appetite, energy expenditure, and ghrelin stimulation pathways as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology 143: 4409-4421, 2002.
26. Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF, and Tohyama M. An arcuato-paraventricular and -dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat. Brain Res 331: 172-175, 1985.
27. Banks WA. The source of cerebral insulin. Eur J Pharmacol 490: 5-12, 2004.
28. Banks WA, Kastin AJ, Huang W, Jaspan JB, and Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides 17: 305-311, 1996.
29. Bannon AW, Seda J, Carmouche M, Francis JM, Norman MH, Karbon B, and McCaleb ML. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 868: 79-87, 2000.
30. Baskin DG, Schwartz MW, Sipols AJ, B'Alessio BA, Goldstein BJ, and White MF. Insulin receptor substrate-1 (IRS-1) expression in rat brain. Endocrinology 134: 1952-1955, 1994.
31. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, and Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948, 2003.
32. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Bakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RB, and Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654, 2002.
33. Batterham RL, Le Roux CW, Cohen MA, Park A, Ellis SM, Patterson M, Frost GS, Ghatei MA, and Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88: 3989-3992, 2003.
34. Baura GB, Foster DM, Porte B Jr, Kahn SE, Bergman EN, Cobelli C, and Schwartz MW. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo A mechanism for regulated insulin delivery to the brain. J Clin Invest 92: 1824-1830, 1993.
35. Bays H and Dujovne C. Pharmacotherapy of obesity, currently marketed and upcoming agents. Am J Cardiovasc Drugs 2: 245-253, 2002.
36. Beglinger C, Degen L, Matzinger B, B'Amato M, and Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am J Physiol Regul Integr Comp Physiol 280: R1149-R11B4, 2001.
37. Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg BJ, Seeley RJ, and Woods SC. The catabolic action of insulin in the brain is mediated by melanocortins. J Neurosci 22: 9048-9052, 2002.
38. Benoit SC, Schwartz MW, Lachey JL, Hagan MM, Rushing PA, Blake KA, Yagaloff KA, Kurylko G, Franco L, Danhoo W, and Seeley RJ. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J Neurosci 20: 3442-3448, 2000.
39. Berg AH, Combs TP, Du X, Brownlee M, and Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953, 2001.
40. Bernardis LL and Bellinger LL. The lateral hypothalamic area revisited: ingestive behavior. Neurosci Biobehav Rev 20: 189-287, 1996.
41. Bernardis LL and Bellinger LL. The dorsomedial hypothalamic nucleus revisited: 1986 update. Brain Res 434: 321-381, 1987.
42. Berntson GG, Zipf WB, O'Dorisio TM, Hoffman JA, and Chance BE. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 14: 497-503, 1993.
43. Berridge KC. Modulation of taste affect by hunger, caloric satiety, and sensory-specific satiety in the rat. Appetite 16: 103-120, 1991.
44. Besterman HS, Cook GC, Sarson DL, Christofides ND, Bryant MG, Gregor M, and Bloom SR. Gut hormones in tropical malabsorption. Br Med J 2: 1252-1255, 1979.
45. Bi S, Ladenheim EE, Schwartz GJ, and Moran TH. A role for NPY overexpression in the dorsomedial hypothalamus in hyperphagia and obesity of OLETF rats. Am J Physiol Regul Integr Comp Physiol 281: R254-R260, 2001.
46. Billington CJ, Briggs JE, Grace M, and Levine AS. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol Regul Integr Comp Physiol 260: R321-R327, 1991.
47. Blevins JE, Stanley BG, and Reidelberger RB. Brain regions where cholecystokinin suppresses feeding in rats. Brain Res 860: 1-10, 2000.
48. Boonacker E and Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82: 53-73, 2003.
49. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Baniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, and Forray C. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8: 825-830, 2002.
50. Bray GA. Afferent signals regulating food intake. Proc Nutr Soc 59: 373-384, 2000.
51. Broadwell RB and Brightman MW. Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. J Comp Neurol 166: 257-283, 1976.
52. Broberger C, De Lecea L, Sutcliffe JG, and Hokfelt T. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J Comp Neurol 402: 460-474, 1998.
53. Broberger C, Johansen J, Johansson C, Schalung M, and Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 95: 15043-15048, 1998.
54. Broberger C, Landry M, Wong H, Walsh JN, and Hokfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 66: 393-408, 1997.
55. Bronstein DM, Schafer MK, Watson SJ, and Akil H. Evidence that beta-endorphin is synthesized in cells in the nucleus tractus solitarius: detection of POMC mRNA. Brain Res 587: 269-275, 1992.
56. Bruning JC, Gautam B, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland B, and Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science 289: 2122-2125, 2000.
57. Bullock BP, Heller RS, and Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978, 1996.
58. Burks DJ, de Mora JF, Schubert M, Withers DJ, Myers MG, Towery HH, Altamuro SL, Flint CL, and White MF. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 407: 377-382, 2000.
59. Butler AA. Studies defining the role of the melanocortin-3 receptor in the development of obesity and insulin resistance (Abstract). Proc Annu Meet Am Endocr Soc 2004.
60. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, and Cone RB. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518-3521, 2000.
61. Cai XJ, Widdowson PS, Harrold J, Wilson S, Buckingham RE, Arch JR, Tadayyon M, Clapham JC, Wilding J, and Williams G. Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 48: 2132-2137, 1999.
62. Callahan HS, Cummings BE, Pepe MS, Breen PA, Matthys CC, and Weigle BS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab 89: 1319-1324, 2004.
63. Campbell RE, Smith MS, Alien SE, Grayson BE, French-Mullen JM, and Grove KL. Orexin neurons express a functional pancreatic polypeptide Y4 receptor. J Neurosci 23: 1487-1497, 2003.
64. Campfield LA, Smith FJ, Guisez Y, Bevos R, and Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546-549, 1995.
65. Challis BG, Coll AP, Yeo GS, Pinnock SB, Dickson SL, Thresher RR, Dixon J, Zahn B, Rochford JJ, White A, Oliver RL, Millington G, Aparicio SA, Colledge WH, Russ AP, Carlton MB, and O'Rahilly S. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci USA 101: 4695-4700, 2004.
66. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, and O'Raliilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311: 915-919, 2003.
67. Chehab FF, Lim ME, and Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12: 318-320, 1996.
68. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, and Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451, 1999.
69. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, and Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor, identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495, 1996.
70. Chen HY, Trumbauer ME, Chen AS, Weingarth DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, Howard AD, MacNeil DJ, and Qian S. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y (NPY) and agouti-related protein (AgRP). Endocrinology 145: 2607-2612, 2004.
71. Chen P, Williams SM, Grove KL, and Smith MS. Melanocortin 4 receptor-mediated hyperphagia and activation of neuropeptide Y expression in the dorsomedial hypothalamus during lactation. J Neurosci 24: 5091-5100, 2004.
72. Cheng X, Broberger C, Tong Y, Yongtao X, Ju G, Zhang X, and Hokfelt T. Regulation of expression of neuropeptide Y Y1 and Y2 receptors in the arcuate nucleus of fasted rats. Brain Res 792: 89-96, 1998.
73. Cheung CC, Clifton DK, and Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 138: 4489-4492, 1997.
74. Christofides ND, Sarson DL, Albuquerque RH, Adrian TE, Ghatei MA, Modlin IM, and Bloom SR. Release of gastrointestinal hormones following an oral water load. Experientia 35: 1521-1523, 1979.
75. Chua SC Jr, Koutras IK, Han L, Liu SM, Kay J, Young SJ, Chung WK, and Leibel RL. Fine structure of the murine leptin receptor gene: splice site suppression is required to form two alternatively spliced transcripts. Genomics 45: 264-270, 1997.
76. Clark JT, Kalra PS, Crowley WR, and Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115: 427-429, 1984.
77. Clark JT, Sahu A, Kalra PS, Balasubramaniam A, and Kalra SP. Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY. Regul Pept 17: 31-39, 1987.
78. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, and Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392: 398-401, 1998.
79. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, and Bloom SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88: 4696-4701, 2003.
80. Coll AP, Challis BG, and ORahilly S. Peptide YY3-36 and satiety: clarity or confusion? Endocrinology 145: 2582-2584, 2004.
81. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, and Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: L113-L117, 1998.
82. Combs TP, Pajvani UB, Berg AU, Lin Y, Jelicks LA, Laplante M, Nawrockl AR, Rajala MW, Parlow AF, Cheeseboro L, Bing YY, Russell HG, Lindemann B, Hartley A, Baker GR, Obici S, Beshaies Y, Ludgate M, Rossetti L, and Scherer PE. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145: 367-383, 2004.
83. Combs TP, Wagner JA, Berger J, Boebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage BB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, and Moller BE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143; 998-1007, 2002.
84. Cone RB, Cowley MA, Butler AA, Fan W, Marks BL, and Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obesity Related Metab Disorders 25 Suppl 5: S63-S67, 2001.
85. Conlon JM. The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP). Peptides 23: 269-278, 2002.
86. Conrad CB and McEwen BS. Acute stress increases neuropeptide Y mRNA within the arcuate nucleus and hilus of the dentate gyrus. Brain Res 79: 102-109, 2000.
87. Considine KV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, and Bauer TL. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295, 1996.
88. 125I-insulin binding sites in the rat hypothalamus by quantitative autoradiography. Neurosci Lett 70: 17-22, 1986.
89. Corpa ES, McQuade J, Krasnicki S, and Conze BB. Feeding after fourth ventricular administration of neuropeptide Y receptor agonists in rats. Peptides 22: 493-499, 2001.
90. Cota B, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer B, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431, 2003.
91. Couceyro PR, Koylu EO, and Kuhar MJ. Further studies on the anatomical distribution of CART by in situ hybridization. J Chem Neuroanat 12: 229-241, 1997.
92. Cowley MA, Pronchuk N, Fan W, Dinulescu BM, Colmers WF, and Cone RB. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24: 155-163, 1999.
93. Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RB, and Horvath TL. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37: 649-661, 2003.
94. Crawley JN and Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302: 703-706, 1983.
95. Crawley JN and Corwin RL. Biological actions of cholecystokinin. Peptides 15: 731-755, 1994.
96. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KK, Frayo RS, Schwartz MW, Basdevant A, and Weigle DS. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8: 643-644, 2002.
97. Cummings DE, Frayo RS, Marmonier C, Aubert R, and Chapelot D. Plasma ghrelin levels and hunger scores among humans initiating meals voluntarily in the absence of time- and food-related cues. Am J Physiol Endocrinol Metab 287: E297-E304, 2004.
98. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, and Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719, 2001.
99. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, and Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623-1630, 2002.
100. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, and Bloom SR. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142: 4244-4250, 2001.
101. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, and Bloom SR. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687-2695, 2004.
102. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, and Bloom SR. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687-2695, 2004.
103. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondai MS, Suganuma T, Matsukura S, Kangawa K, and Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141: 4255-4261, 2000.
104. Date Y, Murakami N, Kojima M, Kuroiwa T, Matsukura S, Kangawa K, and Nakazato M. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun 275: 477-480, 2000.
105. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, and Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120-1128, 2002.
106. Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H, Kojima M, Kangawa K, Arima T, Matsuo H, Yada T, and Matsukura S. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 51: 124-129, 2002.
107. Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD and Van Heek M. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obesity Res 6: 147-156, 1998.
108. Debons AF, Krimsky I, Maayan ML, Fani K, and Jemenez FA. Gold thioglucose obesity syndrome. Federation Proc 36: 143-147, 1977.
109. De Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, and Sutcliffe JG. The hypocretins: hypothalamus-speciflc peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95: 322-327, 1998.
110. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
111. Dhillo WS, Small CJ, Stanley SA, Jethwa PH, Seal LJ, Murphy KG, Ghatei MA, and Bloom SR. Hypothalamic interactions between neuropeptide Y, agouti-related protein, cocaine- and amphetamine-regulated transcript and alpha-melanocyte-stimulating hormone in vitro in male rats. J Neuroendocrinol 14: 725-730, 2002.
112. Di M, V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Mura GI, Palmiter RD, Sugiura T, and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825, 2001.
113. Donahey JC, Van Dijk G, Woods SC, and Seeley RJ. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res 779: 75-83, 1998.
114. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, and Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiol Behav 51: 371-379, 1992.
115. Dumont Y, Fournier A, and Quirion R. Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain. J Neurosci 18: 5565-5574, 1998.
116. Eberlein GA, Eysselein VE, Schaeffer M, Layer P, Grandt D, Goebell H, Niebel W, Davis M, Lee TD, and Shively JE. A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 10: 797-803, 1989.
117. Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, and Bloom SR. The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J Endocrinol 160: R7-R12, 1999.
118. Egawa M, Yoshimatsu H, and Bray GA. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am J Physiol Regul Integr Comp Physiol 260: R328-R334, 1991.
119. Ehrstrom M, Naslund E, Levin F, Kaur R, Kirchgessner AL, Theodorsson E, and Hellstrom PM. Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat. Regul Pept 119: 209-212, 2004.
120. Ekblad E and Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 23: 251-261, 2002.
121. El Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, and Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 105: 1827-1832, 2000.
122. Elias CF, Aschkenasi C, Lee C, Kelly J, Ahima RS, Bjorbaek C, Flier JS, Saper CB, and Elmquist JK. Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area. Neuron 23: 775-786, 1999.
123. Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro PR, Kuhar MJ, Saper CB, and Elmquist JK. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21: 1375-1385, 1998.
124. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, Tatro JB, Hoffman GE, Ollmann MM, Barsh GS, Sakurai T, Yanagisawa M, and Elmquist JK. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 402: 442-459, 1998.
125. Ellacott KL and Cone RD. The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis. Recent Prog Horm Res 59: 395-408, 2004.
126. Ellacott KL, Lawrence CB, Pritchard LE, and Luckman SM. Repeated administration of the anorectic factor prolactin-releasing peptide leads to tolerance to its effects on energy homeostasis. Am J Physiol Regul Integr Comp Physiol 285: R1005-R1010, 2003.
127. Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, and Saper CB. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology 138: 839-842, 1997.
128. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, and Saper CB. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 395: 535-647, 1998.
129. Elmquist JK, Maratos-Flier E, Saper CB, and Flier JS. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1: 445-450, 1998.
130. English PJ, Ghatei MA, Malik IA, Bloom SB, and Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87: 2984, 2002.
131. Fan W, Boston BA, Kesterson RA, Hruby VJ, and Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385: 165-168, 1997.
132. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, and O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341: 879-884, 1999.
133. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, Cheetham T, and O'Rahilly S. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106: 271-279, 2000.
134. Fehmann HC, Jiang J, Schweinfurth J, Wheeler MB, Boyd AE III, and Goke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 15: 453-456, 1994.
135. Fei H, Okano HJ, Li C, Lee GH, Zhao C, Darnell R, and Friedman JM. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci USA 94: 7001-7005, 1997.
136. Fekete C, Legradi G, Mihaly E, Huang QH, Tatro JB, Rand WM, Emerson CH, and Lechan RM. alpha-Melanocyte-stimulating hormone is contained in nerve terminals Innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J Neurosci 20: 1550-1558, 2000.
137. Fekete C, Sarkar S, Rand WM, Harney JW, Emerson CH, Bianco AC, and Lechan RM. Agouti-related protein (AGRP) has a central inhibitory action on the hypothalamic-pituitary-thyroid (HPT) axis: comparisons between the effect of AGRP and neuropeptide Y on energy homeostasis and the HPT axis. Endocrinology 143: 3846-3853, 2002.
138. Flint N. Pharmacotherapy of obesity. Best Pract Res Clin Endocrinol Metab 16: 717-742, 2002.
139. Flint A, Raben A, Ersboll AK, Holst JJ, and Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obesity Related Metab Disorders 25: 781-792, 2001.
140. Flynn MC, Turrin NP, Plata-Salaman CR, and French-Mullen JM. Feeding response to neuropeptide Y-related compounds in rats treated with Y5 receptor antisense or sense phosphothio-oligodeoxynucleotide. Physiol Behav 66: 881-884, 1999.
141. Fodor M, Sluiter A, Frankhuijzen-Sierevogel A, Wiegant VM, Hoogerhout P, De Wildt DJ, and Versteeg DH. Distribution of Lys-gamma 2-melanocyte-stimulating hormone- (Lys-gamma 2-MSH)-like immunoreactivity in neuronal elements in the brain and peripheral tissues of the rat. Brain Res 731: 182-189, 1996.
142. Fogteloo AJ, Pijl H, Frolich M, McCamish M, and Meinders AE. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes Nutr Metab 16: 109-114, 2003.
143. Frederich RC, Lollmann B, Hamann A, Napolitano-Rosen A, Kahn BB, Lowell BB, and Flier JS. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 96: 1658-1663, 1995.
144. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, and Mechoulam R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol 7: 27-34, 2003.
145. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, and Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010, 2001.
146. Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche JP, and Roze C. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflügers Arch 433: 571-579, 1997.
147. Fujimoto S, Inui A, Kiyota N, Seki W, Koide K, Takamiya S, Uemoto M, Nakajima Y, Baba S, and Kasuga M. Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa. Biol Psychiatry 41: 1068-1070, 1997.
148. Fulton S, Woodside B, and Shizgal P. Modulation of brain reward circuitry by leptin. Science 287: 125-128, 2000.
149. Fuxe K, Tinner B, Caberlotto L, Buiuiemann B, and Agnati LF. NPY Y1 receptor like immunoreactivity exists in a subpopulation of beta-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. Neurosci Lett 225: 49-52, 1997.
150. Ge H, Huang L, Pourbahrami T, and Li C. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem 277:45898-45903, 2002.
151. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, and Bloom SR. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57: 488-495, 1983.
152. Gibbs J, Fauser DJ, Rowe EA, Rolls BJ, Rolls ET, and Maddison SP. Bombesin suppresses feeding in rats. Nature 282: 208-210, 1979.
153. Gibbs J, Young RC, and Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84: 488-495, 1973.
154. Giraudo SQ, Billington CJ, and Levine AS. Feeding effects of hypothalamic injection of melanocorbn 4 receptor ligands. Brain Res 809: 302-306, 1998.
155. Glaser B, Zoghlin G, Pienta K, and Vinik AI. Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Horm Metab Res 20: 288-292, 1988.
156. Glass MJ, Chan J, and Pickel VM. Ultrastructural localization of neuropeptide Y Y1 receptors in the rat medial nucleus tractus solitarius: relationships with neuropeptide Y or catecholamine neurons. J Neurosci Res 67: 753-765, 2002.
157. Glover I, Haneef I, Pitts J, Wood S, Moss D, Tickle I, and Blundell T. Conformational flexibility in a small globular hormone: x-ray analysis of avian pancreatic polypeptide at 0.98-A resolution. Biopolymers 22: 293-304, 1983.
158. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, and Reeve JR Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51: 151-159, 1994.
159. Grauerholz BL, Jacobson JD, Handler MS, and Millington WR. Detection of pro-opiomelanocortin mRNA in human and rat caudal medulla by RT-PCR. Peptides 19: 939-948, 1998.
160. Gualillo O, Caminos J, Blanco M, Garcia-Caballero T, Kojima M, Kangawa K, Dieguez C, and Casanueva F. Ghrelin, a novel placental-derived hormone. Endocrinology 142: 788-794, 2001.
161. Guan XM, Yu H, and Van der Ploeg LH. Evidence of altered hypothalamic pro-opiomelanocortin/neuropeptide Y mRNA expression in tubby mice. Brain Res 59: 273-279, 1998.
162. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benliam CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, and Upton N. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96: 10911-10916, 1999.
163. Hagan MM, Castaneda E, Sumaya IC, Fleming SM, Galloway J, and Moss DE. The effect of hypothalamic peptide YY on hippocampal acetylcholine release in vivo: implications for limbic function in binge-eating behavior. Brain Res 805: 20-28, 1998.
164. Hagan MM, Rushing PA, Benoit SC, Woods SC, and Seeley RJ. Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am J Physiol Regul Integr Comp Physiol 280: R814-R821, 2001.
165. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van der Ploeg LH, Woods SC, and Seeley RJ. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol 279: R47-R52, 2000.
166. Hahn TM, Breininger JF, Baskin DG, and Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1: 271-272, 1998.
167. Hakansson ML, Brown H, Ghilardi N, Skoda RC, and Meister B. Leptin receptor immunoreactivity in chemically denned target neurons of the hypothalamus. J Neurosci 18: 559-572, 1998.
168. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, and Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546, 1995.
169. Halatchev IG, Ellacott KL, Fan W, and Cone RD. Peptide YY3-36 inhibits food Intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145: 2585-2590, 2004.
170. Halford JC, Harrold JA, Lawton CL, and Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 6: 201-213, 2005.
171. Hamamura M, Leng G, Emson PC, and Kiyama H. Electrical activation and c-fos mRNA expression in rat neurosecretory neurones after systemic administration of cholecystokinin. J Physiol 444: 51-63, 1991.
172. Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, and Jorgensen JO. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 56: 203-206, 2002.
173. Hao S, Avraham Y, Mechoulam R, and Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392: 147-156, 2000.
174. 125I-neuropeptide Y binding sites in the nucleus tractus soutenus of the normal male rat. Acta Physiol Scand 128: 195-200, 1986.
175. Harrold JA, Widdowson PS, and Williams G. Altered energy balance causes selective changes in melanocortin-4(MC4-R), but not melanocortin-3 (MC3-R), receptors in specific hypothalamic regions: further evidence that activation of MC4-R is a physiological inhibitor of feeding. Diabetes 48: 267-271, 1999.
176. Hattori N, Saito T, Yagyu T, Jiang BH, Kitagawa K, and Inagaki C. GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab 86: 4284-4291, 2001.
177. Haynes AC, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M, and Arch JE. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 20: 1099-1105, 1999.
178. Hayward MD, Pintar JE, and Low MJ. Selective reward deficit in mice lacking beta-endorphin and enkephalin. J Neurosci 22: 8251-8258, 2002.
179. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, and Elmquist JK. Activation of central melanocortin pathways by fenfluramine. Science 297: 609-611, 2002.
180. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, and Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126, 1995.
181. Hetherington AW and Ranson SW. Hypothalamic lesions and adiposity in the rat. Anat Rec 78: 149-172, 1940.
182. Hewson G, Leighton GE, Hill RG, and Hughes J. The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 93: 79-84, 1988.
183. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, and McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282: 1568-1575, 1999.
184. Hinney A, Hoch A, Geller F, Schafer H, Siegfried W, Goldschmidt H, Remschmidt H, and Hebebrand J. Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. J Clin Endocrinol Metab 87: 2716, 2002.
185. Hoentjen F, Hopman WP, and Jansen JB. Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol 36: 1086-1091, 2001.
186. Holst JJ. Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 9: 155-166, 2004.
187. Holst JJ. Glucagon-like peptide 1 (GLP-1): an Intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10: 229-235, 1999.
188. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, and Beck-Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and Insulin in human morbid obesity. Int J Obes 7: 529-538, 1983.
189. Holst JJ, Sorensen TI, Andersen AN, Stadil F, Andersen B, Lauritsen KB, and Klein HC. Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol 14: 205-207, 1979.
190. Horvath TL, Diano S, and van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci 19: 1072-1087, 1999.
191. Hotta K, Funahasni T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
192. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, and Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50: 1126-1133, 2001.
193. Howard JK, Cave BJ, Oksanen LJ, Tzameli I, Bjorbaek C, and Flier JS. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10: 734-738, 2004.
194. Hu E, Liang P, and Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703, 1996.
195. Huang XF, Han M, South T, and Storlien L. Altered levels of POMC, AgRP and MC4-R mRNA expression in the hypothalamus and other parts of the limbic system of mice prone or resistant to chronic high-energy diet-induced obesity. Brain Res 992: 9-19, 2003.
196. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson EA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141, 1997.
197. Ibata Y, Kawakami F, Fukui K, Obata-Tsuto HL, Tanaka M, Kubo T, Okamura H, Morimoto N, Yanaihara C, and Yanaihara N. Light and electron microscopic immunocytochemistry of neurotensin-like immunoreactive neurons in the rat hypothalamus. Brain Res 302: 221-230, 1984.
198. Ikeda H, West DB, Pustek JJ, Figlewicz DP, Greenwood MR, Porte D Jr, and Woods SC. Intraventricular insulin reduces food intake and body weight of lean but not obese Zucker rats. Appetite 7: 381-386, 1986.
199. Inui A. Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol Sci 20: 43-46, 1999.
200. Jamshidi N and Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134: 1151-1154, 2001.
201. Kalia M and Sullivan JM. Brainstem projections of sensory and motor components of the vagus nerve in the rat. J Comp Neurol 211: 248-265, 1982.
202. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, and Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20: 68-100, 1999.
203. Kalra SP, Dube MG, Sahu A, Phelps CP, and Kalra PS. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci USA 88: 10931-10935, 1991.
204. Kanatani A, Ishihara A, Asahi S, Tanaka T, Ozaki S, and Ihara M. Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 137: 3177-3182, 1996.
205. Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S, and Ihara M. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141: 1011-1016, 2000.
206. Kastin AJ, Akerstrom V, and Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18: 7-14, 2002.
207. Katsuura G, Asakawa A, and Inui A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 23: 323-329, 2002.
208. Kawai Y, Inagaki S, SMosaka S, Shibasaki T, Ling N, Tohyama M, and Shiotani Y. The distribution and projection of gamma-melanocyte stimulating hormone in the rat brain: an immunohistochemical analysis. Brain Res 297: 21-32, 1984.
209. Kelly J, Rothstein J, and Grossman SP. GABA and hypothalamic feeding systems. I. Topographic analysis of the effects of rtucroinjections of muscimol. Physiol Behav 23: 1123-1134, 1979.
210. Kim MS, Rossi M, Abusnana S, Sunter D, Morgan DG, Small CJ, Edwards CM, Heatli MM, Stanley SA, Seal LJ, Bhatti JR, Smith DM, Ghatei MA, and Bloom SK. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes 49: 177-182, 2000.
211. Kim MS, Small CJ, Stanley SA, Morgan DG, Seal LJ, Kong WM, Edwards CM, Abusnana S, Sunter D, Ghatei MA, and Bloom SR. The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest 105: 1005-1011, 2000.
212. King PJ, Widdowson PS, Doods UN, and Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 73: 641-646, 1999.
213. King PJ, Williams G, Doods H, and Widdowson PS. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 396: R1-R3, 2000.
214. Kinzig KP, D'Alessio DA, and Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22: 10470-10476, 2002.
215. Kirchgessner AlL and Liu M. Orexin synthesis and response in the gut. Neuron 24: 941-951, 1999.
216. Kissileff HR, Carretta JC, Geliebter A, and Pi-Sunyer FX. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol 285: R992-R998, 2003.
217. Kissileff HE, Pi-Sunyer FX, Thornton J, and Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34: 154-160, 1981.
218. Koch JE. Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 68: 539-543, 2001.
219. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660, 1999.
220. Korbonits M, Gueorguiev M, O'Grady E, Lecoeur C, Swan DC, Mein CA, Weill J, Grossman AB, and Froguel P. A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 87: 4005-4008, 2002.
221. Kreymann B, Williams G, Ghatei MA, and Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304, 1987.
222. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, and Hastrup S. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393: 72-76, 1998.
223. Krude H, Biebermann H, Luck W, Horn R, Brabant G, and Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155-157, 1998.
224. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, and Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277: 25863-25866, 2002.
225. Kuo DY. Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 9: 126-132, 2002.
226. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, and Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci USA 95: 15659-15664, 1998.
227. Kyrkouli SE, Stanley BG, Seirafi RD, and Leibowitz SF. Stimulation of feeding by galanin: anatomical localization and behavioral specificity of this peptide's effects in the brain. Peptides 11: 995-1001, 1990.
228. Ladenheim EE, Moore KA, Salorio CF, Mantey SA, Taylor JE, Coy DH, Jensen RT, and Moran TH. Characterization of bombesin binding sites in the rat stomach. Eur J Pharmacol 319: 245-251, 1997.
229. Lambert PD, Couceyro PK, McGirr KM, Dall Vechia SE, Smith Y, and Kuhar MJ. CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse 29: 293-298, 1998.
230. Lambert PD, Phillips PJ, Wilding JP, Bloom SR, and Herbert J. c-fos expression in the paraventricular nucleus of the hypothalamus following intracerebroventricular infusions of neuropeptide Y. Brain Res 670: 59-65, 1995.
231. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65: 165-174, 1996.
232. Larsson LI and Rehfeld JF. Distribution of gastrin and CCK cells in the rat gastrointestinal tract. Evidence for the occurrence of three distinct cell types storing COOH-terminal gastrin immunoreactivity. Histochemistry 58: 23-31, 1978.
233. Larsson LI, Sundler F, and Hakanson R. Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells. Cell Tissue Res 156: 167-171, 1975.
234. Lassmann V, Vague P, Vialettes B, and Simon MC. Low plasma levels of pancreatic polypeptide in obesity. Diabetes 29: 428-430, 1980.
235. Lawrence CB, Ellacott KL, and Luckman SM. PRL-releasing peptide reduces food intake and may mediate satiety signaling. Endocrinology 143: 360-367, 2002.
236. Lawrence CB, Liu YL, Stock MJ, and Luckman SM. Anorectic actions of prolactin-releasing peptide are mediated by corticotropin-releasing hormone receptors. Am J Physiol Regul Integr Comp Physiol 286: R101-R107, 2004.
237. Lawrence CB, Snape AC, Baudoin FM, and Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 143: 155-162, 2002.
238. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, and Friedman JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379: 632-635, 1996.
239. Lee HM, Udupi V, Englander EW, Rajaraman S, Coffey RJ Jr., and Greeley GH Jr. Stimulatory actions of insulin-like growth factor-I and transforming growth factor-alpha on intestinal neurotensin and peptide YY. Endocrinology 140: 4065-4069, 1999.
240. Lee Y, Yang SP, Soares MJ, and Voogt JL. Distribution of prolactin-releasing peptide mRNA in the rat brain. Brain Res Bull 51: 171-176, 2000.
241. Legradi G and Lechan RM. Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 140: 3643-3652, 1999.
242. Le Quellec A, Kervran A, Blache P, Ciurana AJ, and Bataille D. Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 74: 1405-1409, 1992.
243. Le Roux CW, Aylwyn SJB, Batterham RL, Wynne K, Borg CM, Hunt C, Wedlake L, Monteiro M, Frost GS, Ghatei M, and Bloom S. PYY deficiency may reinforce obesity (Abstract). Br Endocr Soc 7: 42, 2004.
244. Levin BE and Dunn-Meynell AA. Reduced central leptin sensitivity in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 283: R941-R948, 2002.
245. Levine AS, Kneip J, Grace M, and Morley JE. Effect of centrally administered neurotensin on multiple feeding paradigms. Pharmacol Biochem Behav 18: 19-23, 1983.
246. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, and Wong ML. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 101: 4531-4536, 2004.
247. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, and Williams JA. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75: 1144-1152, 1985.
248. Lieverse RJ, Jansen JB, van de ZA, Samson L, Masclee AA, Rovati LC, and Lamers CB. Bombesin reduces food intake in lean man by a cholecystokinin- independent mechanism. J Clin Endocrinol Metab 76: 1495-1498, 1993.
249. Lin HC and Chey WY. Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs. Regul Pept 114: 131-135, 2003.
250. Lin L, Martin R, Schaffhauser AO, and York DA. Acute changes in the response to peripheral leptin with alteration in the diet composition. Am J Physiol Regul Integr Comp Physiol 280: R504-R509, 2001.
251. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, and Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394: 897-901, 1998.
252. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, and Wilkison WO. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371: 799-802, 1994.
253. Lubrano-Berthelier C, Cavazos M, Dubern B, Shapiro A, Stunff CL, Zhang S, Picart F, Govaerts C, Froguel P, Bougneres P, Clement K, and Vaisse C. Molecular genetics of human obesity-associated MC4R mutations. Ann NY Acad Sci 994: 49-57, 2003.
254. Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, Ferron C, Froguel P, and Vaisse C. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 12: 145-153, 2003.
255. MacDonald PE, El Kholy W, Riedel MJ, Salapatek AM, Light PE, and Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 Suppl 3: S434-S442, 2002.
256. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Itondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, and Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737, 2002.
257. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
258. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, and Ranganathan S. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161, 1995.
259. Makimura H, Mizuno TM, Mastaitis JW, Agami R, and Mobbs CV. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 3: 18, 2002.
260. Makino S, Baker RA, Smith MA, and Gold PW. Differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants. J Neuroendocrinol 12: 387-395, 2000.
261. Malaisse-Lagae F, Carpentier JL, Patel YC, Malaisse WJ, and Orci L. Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis Experientia 33: 915-917, 1977.
262. Marks DL, Boucher N, Lanouette CM, Perusse L, Brookhart G, Comuzzie AG, Chagnon YC, and Cone RD. Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans. Am J Med Genet 126: 267-271, 2004.
263. Marks JL, Porte D Jr, Stahl WL, and Baskin DG. Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 127: 3234-3236, 1990.
264. Marsh DJ, Hollopeter G, Kafer KE, and Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4: 718-721, 1998.
265. Marsh DJ, Miura GI, Yagaloff KA, Schwartz MW, Barsh GS, and Palmiter RD. Effects of neuropeptide Y deficiency on hypothalamic agouti-related protein expression and responsiveness to melanocortin analogues. Brain Res 848: 66-77, 1999.
266. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE, Shen Z, Frazier EG, Yu H, Metzger JM, Kuca SJ, Shearman LP, Gopal-Truter S, MacNeil DJ, Strack AM, MacIntyre DE, Van der Ploeg LH, and Qian S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 99: 3240-3245, 2002.
267. Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, and Nakao K. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med 3: 1029-1033, 1997.
268. Matson CA, Reid DF, Cannon TA, and Ritter RC. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278: R882-R890, 2000.
269. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564, 1990.
270. McGowan MK, Andrews KM, and Grossman SP. Chronic intrahypothalamic infusions of insulin or insulin antibodies alter body weight and food intake in the rat. Physiol Behav 51: 753-766, 1992.
271. McLaughlin CL and Baile CA. Obese mice and the satiety effects of cholecystokinin, bombesin and pancreatic polypeptide. Physiol Behav 26: 433-437, 1981.
272. McLaughlin CL, Baile CA, and Buonomo FC. Effect of CCK antibodies on food intake and weight gain in Zucker rats. Physiol Behav 34: 277-282, 1985.
273. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, and Bloom SR. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140: 244-250, 1999.
274. Meereis-Schwanke K, Klonowski-Stumpe H, Herberg L, and Niederau C. Long-term effects of CCK-agonist and -antagonist on food intake and body weight in Zucker lean and obese rats. Peptides 19: 291-299, 1998.
275. Menendez JA and Atrens DM. Insulin and the paraventricular hypothalamus: modulation of energy balance. Brain Res 555: 193-201, 1991.
276. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, and Trayhurn P. Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. J Neuroendocrinol 8: 733-735, 1996.
277. Mercer JG, Moar KM, and Hoggard N. Localization of leptin receptor (Ob-R) messenger ribonucleic acid in the rodent hindbrain. Endocrinology 139: 29-34, 1998.
278. Meryn S, Stein D, and Straus EW. Fasting- and meal-stimulated peptide hormone concentrations before and after gastric surgery for morbid obesity. Metabolism 35: 798-802, 1986.
279. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, and Kahn BB. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428: 569-574, 2004.
280. Miraglia dG, Santoro N, Cirillo G, Raimondo P, Grandone A, D'Aniello A, Di Nardo M, and Perrone L. Molecular screening of the ghrelin gene in Italian obese children: the Leu72Met variant is associated with an earlier onset of obesity. Int J Obes Relat Metab Disord 28: 447-450, 2004.
281. Mochiki E, Inui A, Satoh M, Mizumoto A, and Itoh Z. Motilin is a biosignal controlling cyclic release of pancreatic polypeptide via the vagus in fasted dogs. Am J Physiol Gastrointest Liver Physiol 272: G224-G232, 1997.
282. Moltz JH and McDonald JK. Neuropeptide Y: direct and indirect action on insulin secretion in the rat. Peptides 6: 1155-1159, 1985.
283. Mencarelli M, Maestrini S, Tagliaferri M, Brunani A, Letizia Petroni M, Liuzzi A, and DiBlasio AM. Identification of three novel melanocortin 3 receptor (MC3R) gene mutations in patients with morbid obesity. Am Endocr Soc OR45-1, 2004.
284. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, and O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903-908, 1997.
285. Moran TH, Baldessarini AR, Salorio CF, Lowery T, and Schwartz GJ. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am J Physiol Regul Integr Comp Physiol 272: R1245-R1251, 1997.
286. Moran TH, Katz LF, Plata-Salaman CR, and Schwartz GJ. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol Regul Integr Comp Physiol 274: R618-R625, 1998.
287. Moran TH, Norgren R, Crosby RJ, and McHugh PR. Central and peripheral vagal transport of cholecystokinin binding sites occurs in afferent fibers. Brain Res 526: 95-102, 1990.
288. Moran TH, Robinson PH, Goldrich MS, and McHugh PR. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 362: 175-179, 1986.
289. Moran TH and Schwartz GJ. Neurobiology of cholecystokinin. Crit Rev Neurobiol 9: 1-28, 1994.
290. Moran TH, Smedh U, Kinzig KP, Scott KA, Knipp S, and Ladenheim EE. Peptide YY (3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288: R384-R388, 2005.
291. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, and Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10: 739-743, 2004.
292. Moriguchi T, Sakurai T, Nambu T, Yanagisawa M, and Goto K. Neurons containing orexin in the lateral hypothalamic area of the adult rat brain are activated by insulin-induced acute hypoglycemia. Neurosci Lett 264: 101-104, 1999.
293. Morris BJ. Neuronal localisation of neuropeptide Y gene expression in rat brain. J Comp Neurol 290: 358-368, 1989.
294. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, and Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 8: 1298-1308, 1994.
295. Munro S, Thomas KL, and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
296. Murakami N, Hayashida T, Kuroiwa T, Nakahara K, Ida T, Mondal MS, Nakazato M, Kojima M, and Kangawa K. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats. J Endocrinol 174: 283-288, 2002.
297. Murata M, Okimura Y, Iida K, Matsumoto M, Sowa H, Kaji H, Kojima M, Kangawa K, and Chihara K. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 277: 5667-5674, 2002.
298. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, and Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 409: 194-198, 2001.
299. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, and Hellstom PM. Prandial subcutaneous injections of GLP-1 cause weight loss in obese human subjects. Br J Nutr 91: 439-446, 2003.
300. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, and Hellstrom PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23: 304-311, 1999.
301. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, and Hellstrom PM. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 277: R910-R916, 1999.
302. Naslund E, Gryback P, Hellstrom PM, Jacobsson H, Holst JJ, Theodorsson E, and Backman L. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21: 387-392, 1997.
303. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
304. Naveilhan P, Hassani H, Canals JM, Ekstrand AJ, Larefalk A, Chhajlani V, Arenas E, Gedda K, Svensson L, Thoren P, and Ernfors P. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 5: 1188-1193, 1999.
305. Nicolaidis S and Rowland N. Metering of intravenous versus oral nutrients and regulation of energy balance. Am J Physiol 231: 661-668, 1976.
306. Niswender KD, Morton GJ, Stearns WH, Rhodes CJ, Myers MG Jr, and Schwartz MW. Intracellular signalling Key enzyme in leptin-induced anorexia. Nature 413: 794-795, 2001.
307. Nonaka N, Shioda S, Niehoff ML, and Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther 306: 948-953, 2003.
308. Nowak KW, Mackowiak P, Switonska MM, Fabis M, and Malendowicz LK. Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies. Life Sci 66: 449-454, 2000.
309. Obici S, Feng Z, Karkanias G, Baskin DG, and Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 5: 566-572, 2002.
310. Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, Wada E, and Wada K. Mice lacking bombesin receptor
311. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, and Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138, 1997.
312. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164: 719-721, 1969.
313. O'Shea D, Morgan DG, Meeran K, Edwards CM, Turton MD, Choi SJ, Heath MM, Gunn I, Taylor GM, Howard JK, Bloom CI, Small CJ, Haddo O, Ma JJ, Callinan W, Smith DM, Ghatei MA, and Bloom SR. Neuropeptide Y induced feeding in the rat is mediated by a novel receptor. Endocrinology 138: 196-202, 1997.
314. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M, and Tschop M. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145: 669-673, 2001.
315. Pajvani UB, Du X, Combs TP, Berg AH, Kajala MW, Schulthess T, Engel J, Brownlee M, and Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278: 9073-9085, 2003.
316. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, and Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87: 1797-1804, 2002.
317. Pedersen-Bjergaard U, Host U, Kelbaek H, Schifter S, Rehfeld JF, Faber J, and Christensen NJ. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 56: 497-503, 1996.
318. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, and Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-543, 1995.
319. Peracchi M, Tagliabue R, Quatrini M, and Reschini E. Plasma pancreatic polypeptide response to secretin. Eur J Endocrinol 141: 47-49, 1999.
320. Peyron C, Tighe DK, van den Pol AN, De Lecea L, Heller HC, Sutcliffe JG, and Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18: 9996-10015, 1998.
321. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, and Mantzoros CS. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 51: 1337-1345, 2002.
322. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, Paterniti JR, Srivastava VP, and Young AA. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28: 963-971, 2004.
323. Polonsky KS, Given BD, and Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81: 442-448, 1988.
324. Porte D Jr, Baskin DG, and Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev 60: S20-S29, 2002.
325. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, and Ahima RS. Adiponectin acts in the brain to decrease body weight. Nat Med 10: 524-529, 2004.
326. Qian S, Chen H, Weingarth D, Trumbauer ME, Novi DE, Guan X, Yu H, Shen Z, Feng Y, Frazier E, Chen A, Camacho RE, Shearman LP, Gopal-Truter S, MacNeil DJ, Van der Ploeg LH, and Marsh DJ. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 22: 5027-5035, 2002.
327. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, and Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380: 243-247, 1996.
328. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, and Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38: 916-919, 1996.
329. Raposinho PD, Pedrazzini T, White RB, Palmiter RD, and Aubert ML. Chronic neuropeptide Y infusion into the lateral ventricle induces sustained feeding and obesity in mice lacking either Npy1r or Npy5r expression. Endocrinology 145: 304-310, 2004.
330. Reeve JR Jr, Eysselein VE, Ho FJ, Chew P, Vigna SR, Liddle RA, and Evans C. Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology. Ann NY Acad Sci 713: 11-21, 1994.
331. Reidelberger RD, Hernandez J, Fritzsch B, and Hulce M. Abdominal vagal mediation of the satiety effects of CCK in rats. Am J Physiol Regul Integr Comp Physiol 286: R1005-R1012, 2004.
332. Reidelberger RD and Solomon TE. Comparative effects of CCK-8 on feeding, sham feeding, and exocrine pancreatic secretion in rats. Am J Physiol Regul Integr Comp Physiol 251: R97-R105, 1986.
333. Ricardo JA and Koh ET. Anatomical evidence of direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res 153: 1-26, 1978.
334. Riediger T, Bothe C, Becskei C, and Lutz TA. Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 79: 317-326, 2004.
335. Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, Lechan RM, and Jaenisch K. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 15: 1748-1757, 2001.
336. Roseberry AG, Liu H, Jackson AC, Cai X, and Friedman JM. Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron 41: 711-722, 2004.
337. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D, Abusnana S, Goldstone AP, Russell SH, Stanley SA, Smith DM, Yagaloff K, Ghatei MA, and Bloom SR. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139: 4428-4431, 1998.
338. Sahu A. Resistance to the satiety action of leptin following chronic central leptin infusion is associated with the development of leptin resistance in neuropeptide Y neurones. J Neuroendocrinol 14: 796-804, 2002.
339. Sahu A, Carraway RE, and Wang YP. Evidence that neurotensin mediates the central effect of leptin on food intake in rat. Brain Res 888: 343-347, 2001.
340. Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Furtinger S, Jenkins A, Cox HM, Sperk G, Hokfelt T, and Herzog H. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 99: 8938-8943, 2002.
341. Saito Y, Cheng M, Leslie FM, and Civelli O. Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol 435: 26-40, 2001.
342. Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, Kangawa K, and Sakai T. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23: 531-536, 2002.
343. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, and Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573-585, 1998.
344. Sanacora G, Kershaw M, Finkelstein JA, and White JD. Increased hypothalamic content of preproneuropeptide Y messenger ribonucleic acid in genetically obese Zucker rats and its regulation by food deprivation. Endocrinology 127: 730-737, 1990.
345. Sanchez J, Oliver P, Palou A, and Pico C. The inhibition of gastric ghrelin production by food intake in rats is dependent on the type of macronutrient. Endocrinology 145: 5049-5055, 2004.
346. Saper CB, Chou TC, and Elmquist JK. The need to feed: homeostatic and hedonic control of eating. Neuron 36: 199-211, 2002.
347. Sarkar S and Lechan RM. Central administration of neuropeptide Y reduces alpha-melanocyte-stimulating hormone-induced cyclic adenosine 5′-monophosphate response element binding protein (CREB) phosphorylation in pro-thyrotropin-releasing hormone neurons and increases CREB phosphorylation in corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 144: 281-291, 2003.
348. Sarson DL, Scopinaro N, and Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 5: 471-480, 1981.
349. Sawchenko PE. Central connections of the sensory and motor nuclei of the vagus nerve. J Auton Nerv Syst 9: 13-26, 1983.
350. Sawchenko PE and Swanson LW. The organization and biochemical specificity of afferent projections to the paraventricular and supraoptic nuclei. Prog Brain Res 60: 19-29, 1983.
351. Sawchenko PE, Swanson LW, Grzanna R, Howe PR, Bloom SR, and Polak JM. Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J Comp Neurol 241: 138-153, 1985.
352. Schaffhauser AO, Stricker-Krongrad A, Brunner L, Cumin F, Gerald C, Whitebread S, Criscione L, and Hofbauer KG. Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides. Diabetes 46: 1792-1798, 1997.
353. Scherer PE, Williams S, Fogliano M, Baldini G, and Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746-26749, 1995.
354. Schneider LH. Orosensory self-stimulation by sucrose involves brain dopaminergic mechanisms. Ann NY Acad Sci 575: 307-319, 1989.
355. Schwartz GJ and Moran TH. CCK elicits and modulates vagal afferent activity arising from gastric and duodenal sites. Ann NY Acad Sci 713: 121-128, 1994.
356. Schwartz GJ, Whitney A, Skoglund C, Castonguay TW, and Moran TH. Decreased responsiveness to dietary fat in Otsuka Long-Evans Tokushima fatty rats lacking CCK-A receptors. Am J Physiol Regul Integr Comp Physiol 277: R1144-R1151, 1999.
357. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, and Weigle DS. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 45: 531-535, 1996.
358. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, and Porte D Jr. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 13: 387-414, 1992.
359. Schwartz MW, Seeley RJ, Woods SC, Weigle DS, Campfield LA, Burn P, and Baskin DG. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 46: 2119-2123, 1997.
360. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, and Figlewicz BP. Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 130: 3608-3616, 1992.
361. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, and Baskin DG. Central nervous system control of food intake. Nature 404: 661-671, 2000.
362. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, and Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258, 1996.
363. Seal LJ, Small CJ, Dhillo WS, Stanley SA, Abbott CR, Ghatei MA, and Bloom SR. PRL-releasing peptide inhibits food intake in male rats via the dorsomedial hypothalamic nucleus and not the paraventricular hypothalamic nucleus. Endocrinology 142: 4236-4243, 2001.
364. Segal-Lieberman G, Bradley RL, Kokkotou E, Carlson M, Trombly DJ, Wang X, Bates S, Myers MG Jr, Flier JS, and Maratos-Flier E. Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc Natl Acad Sci USA 100: 10085-10090, 2003.
365. Shimada M, Tritos NA, Lowell BB, Flier JS, and Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396: 670-674, 1998.
366. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, and Nakao K. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50: 227-232, 2001.
367. Shirasaka T, Miyahara S, Kunitake T, Jin QH, Kato K, Takasaki M, and Kannan H. Orexin depolarizes rat hypothalamic paraventricular nucleus neurons. Am J Physiol Regul Integr Comp Physiol 281: R1114-R1118, 2001.
368. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, Campbell-Tmompson M, Crawford J, Shek EW, Searpace PJ, and Zolotukhin S. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 100: 14217-14222, 2003.
369. Shughrue PJ, Lane MV, and Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137: 5159-5162, 1996.
370. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, and Stark KL. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 11: 593-602, 1997.
371. Sipols AJ, Baskin DG, and Schwartz MW. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 44: 147-151, 1995.
372. Small CJ, Kim MS, Stanley SA, Mitchell JR, Murphy K, Morgan DG, Ghatei MA, and Bloom SR. Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes 50: 248-254, 2001.
373. Small CJ, Liu YL, Stanley SA, Connoley IP, Kennedy A, Stock MJ, and Bloom SR. Chronic CNS administration of Agouti-related protein (Agrp) reduces energy expenditure. Int J Obes Related Metab Disorders 27: 530-533, 2003.
374. Smith GP, Jerome C, and Gibbs J. Abdominal vagotomy does not block the satiety effect of bombesin in the rat. Peptides 2: 409-411, 1981.
375. Stanley BG, Chin AS, and Leibowitz SF. Feeding and drinking elicited by central injection of neuropeptide Y: evidence for a hypothalamic site(s) of action. Brain Res Bull 14: 521-524, 1985.
376. Stanley BG, Daniel DR, Chin AS, and Leibowitz SF. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6: 1205-1211, 1985.
377. Stanley BG, Kyrkouli SE, Lampert S, and Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7: 1189-1192, 1986.
378. Stanley BG, Magdalin W, Seirafi A, Thomas WJ, and Leibowitz SF. The perifornical area: the major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s). Brain Res 604: 304-317, 1993.
379. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, and Kriauciunas A. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377: 530-532, 1995.
380. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HE, Ahima RS, and Lazar MA. The hormone resistin links obesity to diabetes. Nature 409: 307-312, 2001.
381. Stratford TR and Kelley AE. Evidence of a functional relationship between the nucleus accumbens shell and lateral hypothalamus subserving the control of feeding behavior. J Neurosci 19: 11040-11048, 1999.
382. Strobel A, Issad T, Camoin L, Ozata M, and Strosberg AB. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18: 213-215, 1998.
383. Strubbe JH and Mein CG. Increased feeding in response to bilateral injection of insulin antibodies in the VMH. Physiol Behav 19: 309-313, 1977.
384. Sugino T, Yamaura J, Yamagishi M, Ogura A, Hayashi R, Kurose Y, Kojima M, Kangawa K, Hasegawa Y, and Terashima Y. A transient surge of ghrelin secretion before feeding is modified by different feeding regimens in sheep. Biochem Biophys Res Commun 298: 785-788, 2002.
385. Sul HS. Resistin/ADSF/FIZZ3 in obesity and diabetes. Trends Endocrinol Metab 15: 247-249, 2004.
386. Sun Y, Ahmed S, and Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23: 7973-7981, 2003.
387. Sun Y, Wang P, Zheng H, and Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101: 4679-4684, 2004.
388. Swart I, Jahng JW, Overton JM, and Houpt TA. Hypothalamic NPY, AGRP, and POMC mRNA responses to leptin and refeeding in mice. Am J Physiol Regul Integr Comp Physiol 283: R1020-R1026, 2002.
389. Szczypka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, and Palmiter RD. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30: 819-828, 2001.
390. Tamura H, Kamegai J, Shimizu T, Ishii S, Sugihara H, and Oikawa S. Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology 143: 3268-3275, 2002.
391. Tang-Christensen M, Vrang N, and Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47: 530-537, 1998.
392. Tang-Christensen M, Vrang N, and Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Related Metab Disorders 25 Suppl 5: S42-S47, 2001.
393. Tartaglia LA. The leptin receptor. J Biol Chem 272: 6093-6096, 1997.
394. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, and Deeds J. Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995.
395. Ter Horst GJ, de Boer P, Luiten PG, and van Willigen JD. Ascending projections from the solitary tract nucleus to the hypothalamus. A Phaseolus vulgaris lectin tracing study in the rat. Neuroscience 31: 785-797, 1989.
396. Thorsell A and Heilig M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides 36: 182-193, 2002.
397. Todd JF, Stanley SA, Roufosse CA, Bishop AE, Khoo B, Bloom SR, and Meeran K. A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes. Lancet 361: 228-230, 2003.
398. Torsello A, Locatelli V, Melis MR, Succu S, Spano MS, Deghenghi R, Muller EE, and Argiolas A. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 72: 327-332, 2000.
399. Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan JL, Wang QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kangawa K, and Nakazato M. Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 144: 1506-1512, 2003.
400. Track NS, McLeod RS, and Mee AV. Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. Can J Physiol Pharmacol 58: 1484-1489, 1980.
401. Tsao TS, Lodish HF, and Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440: 213-221, 2002.
402. Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-sickinger AG, Koglin N, Rodgers W, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML, and Withcomb DC. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430: 1, 2004.
403. Tschop M, Smiley DL, and Heiman ML. Ghrelin induces adiposity in rodents. Nature 407: 908-913, 2000.
404. Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, and Folwaczny C. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24: RC19-RC21, 2001.
405. Turnbull AV, Ellershaw L, Masters DJ, Birtles S, Boyer S, Carroll D, Clarkson P, Loxham SJ, McAulay P, Teague JL, Foote KM, Pease JE, and Block MH. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes 51: 2441-2449, 2002.
406. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, and Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
407. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki JI, and Kasuga M. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117: 1427-1432, 1999.
408. Uhe AM, Szmukler GI, Collier GR, Hansky J, O'Dea K, and Young GP. Potential regulators of feeding behavior in anorexia nervosa. Am J Clin Nutr 55: 28-32, 1992.
409. Ukkola O, Ravussin E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L, and Bouchard C. Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 10: 782-791, 2002.
410. Uttenthal LO, Toledano A, and Blazquez E. Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 21: 143-146, 1992.
411. Vaisse C, Halaas JL, Horvath CM, Darnell JE Jr, Stoffel M, and Friedman JM. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 14: 95-97, 1996.
412. Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, and Kumar S. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53: 430-434, 2004.
413. Van der Koy D, Koda LY, McGinty JF, Gerfen CR, and Bloom FE. The organization of projections from the cortex, amygdala, and hypothalamus to the nucleus of the solitary tract in rat. J Comp Neurol 224: 1-24, 1984.
414. Van Dijk G, Thiele TE, Donahey JC, Campfield LA, Smith FJ, Burn P, Bernstein IL, Woods SC, and Seeley RJ. Central infusions of leptin and GLP-1-(T-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol Regul Integr Comp Physiol 271: R1096-R1100, 1996.
415. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, and Davis HB Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 99: 385-390, 1997.
416. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, and Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86: 4382-4389, 2001.
417. Verdich C, Toubro S, Buemann B, Lysgard MJ, Juul HJ, and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Related Metab Disorders 25:1206-1214, 2001.
418. Verty AN, McFarlane JR, McGregor IS, and Mallet PE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145: 3224-3231, 2004.
419. Wang HJ, Geller F, Dempfle A, Schauble N, Friedel S, Lichtner P, Fontenla-Horro F, Wudy S, Hagemann S, Gortner L, Huse K, Remschmidt H, Bettecken T, Meitinger T, Schafer H, Hebebrand J, and Hinney A. Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J Clin Endocrinol Metab 89: 157-162, 2004.
420. Wang L, Saint-Pierre DH, and Tache Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y-synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci Lett 325: 47-51, 2002.
421. Wank SA, Harkins R, Jensen RT, Shapira H, de Weerth A, and Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 89: 3125-3129, 1992.
422. Wank SA, Pisegna JR, and de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 89: 8691-8695, 1992.
423. Watson SJ and Akil H. The presence of two alpha-MSH positive cell groups in rat hypothalamus. Eur J Pharmacol 58: 101-103, 1979.
424. Wei Y and Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358: 219-224, 1995.
425. West DB, Fey D, and Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol Regul Integr Comp Physiol 246: R776-R787, 1984.
426. West DB, Greenwood MR, Sullivan AC, Prescod L, Marzullo LR, and Triscari J. Infusion of cholecystokinin between meals into free-feeding rats fails to prolong the intermeal interval. Physiol Behav 39: 111-115, 1987.
427. Whitcomb DC, Taylor IL, and Vigna SR. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol Gastrointest Liver Physiol 259: G687-G691, 1990.
428. White JD, Olchovsky D, Kershaw M, and Berelowitz M. Increased hypothalamic content of preproneuropeptide-Y messenger ribonucleic acid in streptozotocin-diabetic rats. Endocrinology 126: 765-772, 1990.
429. Widdowson PS, Upton R, Henderson L, Buckingham R, Wilson S, and Williams G. Reciprocal regional changes in brain NPY receptor density during dietary restriction and dietary-induced obesity in the rat. Brain Res 774: 1-10, 1997.
430. Wieland HA, Engel W, Eberlein W, Rudolf K, and Doods HN. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 125: 549-555, 1998.
431. Wilding JP, Gilbey SG, Bailey CJ, Batt RA, Williams G, Ghatei MA, and Bloom SR. Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 132: 1939-1944, 1993.
432. Williams CM and Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143: 315-317, 1999.
433. Williams CM, Rogers PJ, and Kirkham TC. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol Behav 65: 343-346, 1998.
434. Williams DL, Kaplan JM, and Grill HJ. The role of the dorsal vagal complex and the vagus nerve in feeding effects of melanocortin-3/4 receptor stimulation. Endocrinology 141: 1332-1337, 2000.
435. Williams G, Gill JS, Lee YC, Cardoso HM, Okpere BE, and Bloom SR. Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozocin-induced diabetic rats. Diabetes 38: 321-327, 1989.
436. Wisen O, Bjorvell H, Cantor P, Johansson C, and Theodorsson E. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept 39: 43-54, 1992.
437. Woods SC, Decke E, and Vasselli JR. Metabolic hormones and regulation of body weight. Psychol Rev 81: 26-43, 1974.
438. Woods SC, Lotter EC, McKay LD, and Porte D Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282: 503-505, 1979.
439. Woods SC, Seeley RJ, Baskin DG, and Schwartz MW. Insulin and the blood-brain barrier. Curr Pharm Des 9: 795-800, 2003.
440. Woods SC, Stein LJ, McKay LD, and Porte D Jr. Suppression of food intake by intravenous nutrients and insulin in the baboon. Am J Physiol Regul Integr Comp Physiol 247: R393-R401, 1984.
441. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, and Bloom SR. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86: 5992, 2001.
442. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, and Bloom SR. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50: 2540-2547, 2001.
443. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, and Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141: 4325-4328, 2000.
444. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, Tecott LH, and Reichardt LF. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 6: 736-742, 2003.
445. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, and Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23: 2939-2946, 2003.
446. Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, and Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 849: 248-252, 1999.
447. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, and Kadowaki T. Cloning of adlponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769, 2003.
448. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.
449. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, and Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: 3815-3819, 2001.
450. Yasuda T, Masaki T, Kakuma T, and Yoshimatsu H. Hypothalamic melanocortin system regulates sympathetic nerve activity in brown adipose tissue. Exp Biol Med 229: 235-239, 2004.
451. Yeomans MR, Wright P, Macleod HA, and Critchley JA. Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability. Psychopharmacology 100: 426-432, 1990.
452. Yokosuka M, Xu B, Pu S, Kalra PS, and Kalra SP. Neural substrates for leptin and neuropeptide Y (NPY) interaction: hypothalamic sites associated with inhibition of NPY-induced food intake. Physiol Behav 64: 331-338, 1998.
453. Yoshihara T, Honma S, and Honma K. Effects of restricted daily feeding on neuropeptide Y release in the rat paraventricular nucleus. Am J Physiol Endocrinol Metab 270: E589-E595, 1996.
454. Zander M, Madsbad S, Madsen JL, and Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002.
455. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, and Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 133: 1753-1758, 1993.
456. Zhang M, Balmadrid C, and Kelley AE. Nucleus accumbens opioid, GABAergic, and dopaminergic modulation of palatable food motivation: contrasting effects revealed by a progressive ratio study in the rat. Behav Neurosci 117: 202-211, 2003.
457. Zhang M and Kelley AE. Enhanced intake of high-fat food following striatal mu-opioid stimulation: microrojection mapping and fos expression. Neuroscience 99: 267-277, 2000.
458. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.
459. Zheng H, Corkern MM, Crousillac SM, Patterson LM, Phifer CB, and Berthoud HR. Neurochemical phenotype of hypothalamic neurons showing Fos expression 23 h after intracranial AgRP. Am J Physiol Regul Integr Comp Physiol 282: R1773-R1781, 2002.
460. Zipf WB, O'Dorisio TM, Cataland S, and Dixon K. Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome. J Clin Endocrinol Metab 57: 1074-1080, 1983.
461. Zipf WB, O'Dorisio TM, Cataland S, and Sotos J. Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. J Clin Endocrinol Metab 52: 1264-1266, 1981.